Results 21 to 30 of about 16,542 (247)

Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient

Journal of Dermatological Treatment, 2023
Uveitis is a rare adverse event of dupilumab, that typically affects both eyes and often leads to discontinuation of therapy. In this article, we report a case of a 28-year-old female with atopic dermatitis who developed new-onset iridocyclitis, a form ...
Shiyu Zhang, Lu Lu, Jindi Feng, Zhonghui Hu, Hongbin Song, Lu Yang, Yuehua Liu, Di Chen, Tao Wang   +8 more
doaj   +1 more source

Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase

Scientific Reports, 2021
Dupilumab is a dual inhibitor of interleukin-4 and interleukin-13 and is mainly used to treat moderate-to-severe atopic dermatitis. Post-marketing safety data related to dupilumab have been accumulated, and it has been found that ocular surface diseases ...
Sunny Park, Jung Hyun Lee, Ji Hyun Park, So Hyang Park, Song Yi Park, Yong Woo Jung, Soo An Choi   +6 more
doaj   +1 more source

Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP

BMC Pulmonary Medicine, 2022
Background Dupilumab, an anti-IL-4α receptor antibody, is a new treatment for severe or refractory asthma. However, real-world evidence on the efficacy of dupilumab in patients with mild to moderate bronchial asthma is lacking. Methods We retrospectively
Shunsuke Minagawa, Jun Araya, Naoaki Watanabe, Shota Fujimoto, Junko Watanabe, Hiromichi Hara, Takanori Numata, Kazuyoshi Kuwano, Yoshinori Matsuwaki   +8 more
doaj   +1 more source

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid [PDF]

, 2021
Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series.
Bossart, Simon, Schlapbach, Christoph, Borradori, Luca, Feldmeyer, Laurence, Seyed Jafari, S. Morteza, Simon, Dagmar, Simon Bossart, S. Morteza Seyed Jafari, Laurence Feldmeyer, Luca Borradori, Dagmar Simon, Christoph Schlapbach   +11 more
core   +2 more sources

Facial redness in Japanese adolescents with atopic dermatitis treated with dupilumab: A case series

Journal of Allergy and Clinical Immunology: Global, 2023
This case series study is the first report of Japanese adolescents who experienced dupilumab facial redness after starting dupilumab treatment for refractory atopic dermatitis.
Shuhei Hara, MD, Takaaki Itonaga, MD, Makoto Nishino, MD, Noriyuki Yanagida, MD, PhD, Sakura Sato, MD, Motohiro Ebisawa, MD, PhD   +5 more
doaj   +1 more source

Dupilumab-associated ocular surface disease: a case report

, 2022
Aims: Australian dermatologists are becoming familiar with prescribing dupilumab since it was listed on the PBS on the 1st March 2021. The presentation, management and long-term sequelae of dupilumab-associated ocular surface disease is discussed as ...
Sander, Christina, O'Bryen, John
core   +1 more source

Dupilumab‐induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis [PDF]

, 2023
BACKGROUND Dupilumab, a monoclonal anti-IL-4Rα antibody, is approved for several type 2 mediated inflammatory diseases like asthma, atopic dermatitis, and diffuse type 2 chronic rhinosinusitis (CRS).
Steiner, Urs C, Brühlmann, Catrin, Alan Valaperti, Yalamanoglu, Ayla, Stephan Traidl, Michael B. Soyka, Catrin Brühlmann, Soyka, Michael B, Urs C. Steiner, Ayla Yalamanoglu, Fabio S. Ryser, Mauthe, Tina, Tina Mauthe, Valaperti, Alan, Ryser, Fabio S, Traidl, Stephan, Steiner, Urs C; https://orcid.org/, Ryser, Fabio S; https://orcid.org/   +17 more
core   +2 more sources

Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD)

International Journal of Women's Dermatology, 2019
Background: The mechanisms underlying eye-related complications with dupilumab are poorly understood. Objective: This study aimed to determine the incidence and characteristics of ocular complications with dupilumab and the prevalence of comorbid ...
Jodie Raffi, BA, Raagini Suresh, BS, Harvey Fishman, MD, PhD, Nina Botto, MD, Jenny E. Murase, MD   +4 more
doaj   +1 more source

Eosinophilic Gastritis in a Patient Previously Treated with Dupilumab [PDF]

, 2020
A 77-year-old Japanese man with bronchial asthma was treated with dupilumab. Dupilumab treatment was discontinued at the patient's request after two injections separated by a 2-week interval.
Iwamuro, Masaya, Tanaka, Takehiro, Murakami, Toshi, Oka, Shohei, Kawahara, Yoshiro, Okada, Hiroyuki, Kawano, Seiji   +6 more
core   +2 more sources

Conjunctivitis in dupilumab clinical trials [PDF]

, 2019
BACKGROUND: Dupilumab, which blocks the shared receptor component for interleukin (IL)-4 and IL-13, is approved for inadequately-controlled moderate-to-severe atopic dermatitis (AD) and moderate-to-severe eosinophilic or oral corticosteroid-dependent ...
Akpek, E., Akpek, E, Chen, Z., Mannent, L., de Bruin-Weller, M., Hirano, I, Simpson, EL, Wollenberg, A., Wollenberg, A. (A.), Graham, N.M.H., Cork, MJ, Pirozzi, G, Prens, E., Weyne, J., Asbell, P., Corren, J, Zhu, X, Corren, J., Hamilton, J.D., Hultsch, T., Bachert, Claus, Davis, JD, Simpson, E.L., Ardeleanu, M., Bruin-Weller, M, Bachert, C., Shumel, B., Prens, E.P. (Errol), Shumel, B, Cork, M.J., Asbell, P, Guttman-Yassky, E, Bachert, C, Guttman-Yassky, E., Chen, Z, Davis, J.D., Bruin-Weller, M. (Marjolein), Weyne, J, Staudinger, H, Staudinger, H., Mannent, L, Blauvelt, A., Teper, A., Graham, NMH, Guttman-Yassky, E. (Emma), Hamilton, JD, Bruin‐Weller, M., Zhu, X.D. (Xiaoye), Hultsch, T, Zhu, X., Korotzer, A, Akinlade, B, Hirano, I., Bachert, C. (Claus), Wollenberg, A, Rizova, E, Guttman‐Yassky, E., Blauvelt, A, Prens, Errol, Rizova, E., Pirozzi, G., Akinlade, B., Chen, Z. (Zhongli), Teper, A, Ardeleanu, M, Korotzer, A., Prens, E, de, Bruin-Weller M   +67 more
core   +3 more sources